LivaNova PLC Deferred Tax Assets, in Process Research and Development
LivaNova PLC (LIVN) had Deferred Tax Assets, in Process Research and Development of $17.41 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $17.41M.
- 2024-12-31: Deferred Tax Assets, in Process Research and Development $30.82M.
- 2023-12-31: Deferred Tax Assets, in Process Research and Development $26.74M.
- 2022-12-31: Deferred Tax Assets, in Process Research and Development $29.80M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2025-12-31 | $17.41M 10-K · filed 2026-02-25 |
| 2024-12-31 | $30.82M 10-K · filed 2026-02-25 |
| 2023-12-31 | $26.74M 10-K · filed 2025-02-25 |
| 2022-12-31 | $29.80M 10-K · filed 2024-02-29 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |